Five pharmaceutical companies said on Friday they have filed a complaint in a Canadian court challenging the constitutionality of new Canadian regulations meant to lower patented drug prices, setting up a fight with the federal government ahead of an Oct. 21 election.
TORONTO Canada's patented drug price regulator, set to gain new powers next year, may be "more forgiving" in setting price caps for drugs that treat rare diseases, the agency's executive director told Reuters, as some advocates warned the country's pricing reforms would hurt patients.
TORONTO The Canadian government announced final regulations on Friday that should cut billions of dollars from patented drug prices that are among the highest in the world, overcoming heavy opposition from pharmaceutical companies who may eventually challenge the new rules in court.
TORONTO Canada's main pharmaceutical lobby group has urged the government not to wait for drug shortages before responding to U.S. plans to import Canadian drugs, according to documents seen by Reuters.
TORONTO/MONTREAL Canada's two most populous provinces, Ontario and Quebec, have privately expressed concerns with a federal government plan to slash the price of patented drugs, arguing that such regulatory changes could hurt investment in life sciences.
TORONTO Canada opposes any U.S. plans to buy Canadian prescription drugs that might threaten the country's drug supply or raise costs for its own citizens, officials have told U.S. authorities, in a new setback to the Trump administration's efforts to tackle high drug prices, according to documents obtained by Reuters.
OTTAWA/TORONTO A Canadian advisory council studying prescription drug coverage said on Wednesday the federal government should create a C$15.3 billion ($11.5 billion) universal, single-payer public pharmacare system, and warned that the current system requires a major overhaul.
TORONTO The Canadian government has assured the pharmaceutical industry that new features of its plan to cut drug costs would apply only to new medicines, Health Canada said, offering some relief to drugmakers even as other regulations could still lower prices of medicines already on the market.